Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: First feasibility study

Gynecologic Oncology

Volumn 81, Issue 1, 2001, Pages 53-57

  Frigerio, Luigi ^a   Mangili, Giorgia ^a   Aletti, Giovanni ^a   Carnelli, Marco ^a   Garavaglia, Elisabetta ^a   Beatrice, Saverio ^a   Ferrari, Augusto ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME;

EID: 0035059153     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.6088     Document Type: Article

References (31)

1. Endometrial cancer
2. Endometrial cancer: Risk factors and diagnosis
3. Stage IVB endometrial carcinoma: The role of cytoreductive surgery and determinants of survival
4. FIGO stages 1988 revision
5. Clinical stage I endometrial cancer: Prognostic factors for local control and distant metastasis and implications of the new Figo surgical staging system
6. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study
7. Deoxyribonucleic acid analysis facilitates the pretreatment identification of high-risk endometrial cancer patients
8. Prognostic value of flow cytometric deoxyribonucleic acid index in endometrial carcinoma: Comparison with other clinical-pathologic parameters
9. Endometrial neoplasia: Prognostic significance of ploidy status
10. Postoperative exteranl irradiation and prognostic parameters in stage I endometrial carcinoma
11. Prognostic factors and sites of failure in FIGO I grade 3 endometrial carcinoma
12. Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery
13. Vaginal recurrences of endometrial carcinoma: The prognostic value of staging by a primary vaginal carcinoma system
14. Endometrial carcinoma - Relative effectiveness of adjuvant irradiation vs therapy reserved for relapse
15. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: A Gynecologic Oncology Group study
16. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma
17. External pelvic radiation therapy in stage IC endometrial carcinoma
18. A phase III randomized study of surgery versus surgery plus adjuntive dadiation therapy in intermediate risk endometrial cancer
19. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high risk endometrial carcinoma
20. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high risk endometrial carcinoma stage I and occult stage II
21. Risk groups and adjuvant therapy in surgical staged endometrial cancer patients. A randomized multicenter study comparing chemotherapy with radiation therapy
22. Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer
23. Disruption of microtubules in living cells by tyrphostin AG-1714
24. Paclitaxel sensitizes multidrug resistant cells to radiation
25. Cytotoxicity and cell-cycle effects of paclitaxel when used as single agent and in combination with ionizing radiation
26. Phase I trial of outpatient weekly paclitaxel and concurrent radiotherapy for advanced non small cell lung cancer
27. Paclitaxel and simultaneous radiation in the treatment of non small cell lung cancer
28. Phase II study of concurrent chemoradiotherapy for inoperable (bulky) stage III (A/B) non-small cell lung cancer (NSCLC): A preliminary report
29. Paclitaxel and concurrent radiation therapy for locally advanced carcinoma of the pancreas, stomach and gastroesophageal junction
30. Weekly paclitaxel as a radiation sensitizer for locally advanced pancreatic cancers: The Brown University Oncology Group experience
31. One hour paclitaxel infusion: Review of safety and efficacy